摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

methyl 1,2-dimethyl-1H-benzimidazole-6-carboxylate | 1038387-93-7

中文名称
——
中文别名
——
英文名称
methyl 1,2-dimethyl-1H-benzimidazole-6-carboxylate
英文别名
2,3-dimethyl-benzimidazole-5-carboxylic acid methyl ester;Methyl 1,2-dimethyl-1H-benzo[d]imidazole-6-carboxylate;methyl 2,3-dimethylbenzimidazole-5-carboxylate
methyl 1,2-dimethyl-1H-benzimidazole-6-carboxylate化学式
CAS
1038387-93-7
化学式
C11H12N2O2
mdl
——
分子量
204.228
InChiKey
VJPIFJLLMVPXQE-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.7
  • 重原子数:
    15
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.27
  • 拓扑面积:
    44.1
  • 氢给体数:
    0
  • 氢受体数:
    3

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    methyl 1,2-dimethyl-1H-benzimidazole-6-carboxylateN,N-二异丙基乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 、 sodium hydroxide 作用下, 以 甲醇N,N-二甲基甲酰胺 为溶剂, 生成 N-[1-(5-chloro-2-methoxypyridin-4-yl)azetidin-3-yl]-2,3-dimethylbenzimidazole-5-carboxamide
    参考文献:
    名称:
    Discovery of a novel 2,3-dimethylimidazo[1,2-a]pyrazine-6-carboxamide M4 positive allosteric modulator (PAM) chemotype
    摘要:
    This Letter details our efforts to discover structurally unique M-4 PAMs containing 5,6-heteroaryl ring systems. In an attempt to improve the DMPK profiles of the 2,3-dimethyl-2H-indazole-5-carboxamide and 1-methyl-1H-benzo[d][1,2,3]triazole-6-carboxamide cores, we investigated a plethora of core replacements. This exercise identified a novel 2,3-dimethylimidazo[1,2-a]pyrazine-6-carboxamide core that provided improved M-4 PAM activity and CNS penetration.
    DOI:
    10.1016/j.bmcl.2019.126812
  • 作为产物:
    描述:
    3-(甲基氨基)-4-硝基苯羧酸甲酯盐酸 、 palladium on activated charcoal 、 氢气 作用下, 以 乙酸乙酯 为溶剂, 生成 methyl 1,2-dimethyl-1H-benzimidazole-6-carboxylate
    参考文献:
    名称:
    Synthesis and antiprotozoal activity of nitazoxanide–N-methylbenzimidazole hybrids
    摘要:
    A series of a novel hybrid compounds between nitazoxanide and N-methylbenzimidazole were synthesized starting from the corresponding N-methyl-2-nitroanilines. The new hybrid compounds (1-13) were evaluated in vitro against Giardia intestinalis, Entamoeba histolytica, Trichomonas vaginalis. NTZ, MTZ and ABZ were used as drug standards. Experimental evaluations revealed all of the new compounds (1-13) were active and showed strong activity against the three protozoa, particularly with E. histolytica where the IC50 values ranged between 3 and 69 nM.Overall, compounds 2, 5, 7, 8, 9, 11 and 12 stood out with values lower than 87 nM for all three protozoa, comparatively better than the reference drugs. (C) 2013 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2013.10.011
点击查看最新优质反应信息

文献信息

  • NOVEL JNK INHIBITORS
    申请人:Reddy Panduranga Adulla P.
    公开号:US20100298314A1
    公开(公告)日:2010-11-25
    Disclosed are substituted imidazo[1,2-a]pyridines, imidazo[1,2-a]pyrazines, imidazo[1,2-c]pyrimidines and imidazo[1,2-d]triazines compounds of the formula: (1.0) Also disclosed are methods for treating JNK1 and ERK mediated diseases using the compounds of formula 1.0.
    本发明涉及代替的咪唑[1,2-a]吡啶,咪唑[1,2-a]吡嗪,咪唑[1,2-c]嘧啶和咪唑[1,2-d]三嗪化合物,其化学式为:(1.0)。本发明还涉及使用化合物1.0治疗JNK1和ERK介导的疾病的方法。
  • WO2008/82490
    申请人:——
    公开号:——
    公开(公告)日:——
  • [EN] NOVEL JNK INHIBITORS<br/>[FR] NOUVEAUX INHIBITEURS DE JNK
    申请人:SCHERING CORP
    公开号:WO2008082490A2
    公开(公告)日:2008-07-10
    [EN] Disclosed are substituted imidazo[1,2-a]pyridines, imidazo[1,2-a]pyrazines, imidazo[1,2-c]pyrimidines and imidazo[1,2-d]triazines compounds of the formula: (1.0) Also disclosed are methods for treating JNK1 and ERK mediated diseases using the compounds of formula 1.0.
    [FR] L'invention concerne des composés imidazo[1,2-a]pyridines, imidazo[1,2-a]pyrazines, imidazo[1,2-c]pyrimidines et imidazo[-,2-d]triazines, représentés par les formules : (1.0). L'invention concerne également des procédés de traitement de maladies à médiation par JNK1 et ERK à l'aide des composés représentés par la formule 1,0.
  • Discovery of a novel 2,3-dimethylimidazo[1,2-a]pyrazine-6-carboxamide M4 positive allosteric modulator (PAM) chemotype
    作者:Kayla J. Temple、Julie L. Engers、Madeline F. Long、Katherine J. Watson、Sichen Chang、Vincent B. Luscombe、Matthew T. Jenkins、Alice L. Rodriguez、Colleen M. Niswender、Thomas M. Bridges、P. Jeffrey Conn、Darren W. Engers、Craig W. Lindsley
    DOI:10.1016/j.bmcl.2019.126812
    日期:2020.2
    This Letter details our efforts to discover structurally unique M-4 PAMs containing 5,6-heteroaryl ring systems. In an attempt to improve the DMPK profiles of the 2,3-dimethyl-2H-indazole-5-carboxamide and 1-methyl-1H-benzo[d][1,2,3]triazole-6-carboxamide cores, we investigated a plethora of core replacements. This exercise identified a novel 2,3-dimethylimidazo[1,2-a]pyrazine-6-carboxamide core that provided improved M-4 PAM activity and CNS penetration.
  • Synthesis and antiprotozoal activity of nitazoxanide–N-methylbenzimidazole hybrids
    作者:Olivia Soria-Arteche、Alicia Hernández-Campos、Lilián Yépez-Mulia、Pedro Josué Trejo-Soto、Francisco Hernández-Luis、Jorge Gres-Molina、Luis A. Maldonado、Rafael Castillo
    DOI:10.1016/j.bmcl.2013.10.011
    日期:2013.12
    A series of a novel hybrid compounds between nitazoxanide and N-methylbenzimidazole were synthesized starting from the corresponding N-methyl-2-nitroanilines. The new hybrid compounds (1-13) were evaluated in vitro against Giardia intestinalis, Entamoeba histolytica, Trichomonas vaginalis. NTZ, MTZ and ABZ were used as drug standards. Experimental evaluations revealed all of the new compounds (1-13) were active and showed strong activity against the three protozoa, particularly with E. histolytica where the IC50 values ranged between 3 and 69 nM.Overall, compounds 2, 5, 7, 8, 9, 11 and 12 stood out with values lower than 87 nM for all three protozoa, comparatively better than the reference drugs. (C) 2013 Elsevier Ltd. All rights reserved.
查看更多